ModerateOther opioids×Antidepressant (other antidepressants, N06AX)
Updated · Methodology
Mechanism
Vortioxetine is an antidepressant with serotonergic activity, and its prescribing information names tramadol among the opioids that can cause serotonin syndrome when combined with it (vortioxetine summary of product characteristics, SmPC, European Medicines Agency, EMA). Tramadol itself is a weak serotonin and norepinephrine reuptake inhibitor and also acts on mu-opioid receptors (tramadol label, US Food and Drug Administration, FDA). Both drugs lower the seizure threshold. Serotonergic antidepressants may lower it (vortioxetine SmPC, EMA). Tramadol can cause seizures and adds to the seizure risk of drugs that lower the threshold (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In healthy volunteers vortioxetine did not inhibit CYP2D6 or CYP3A4 (vortioxetine SmPC, EMA), the enzymes that turn tramadol into its active metabolite and break it down (tramadol SmPC, AEMPS). The documents describe no effect of vortioxetine on tramadol levels.
Symptoms
Serotonin syndrome changes mental status: agitation and hallucinations appear, and severe cases progress to coma. The heart rate rises, blood pressure becomes unstable, temperature goes up, reflexes become brisk and coordination is impaired. Nausea, vomiting and diarrhoea may occur (vortioxetine summary of product characteristics, SmPC, European Medicines Agency, EMA). Symptoms usually start within several hours to a few days of combined use but may appear later (tramadol label, US Food and Drug Administration, FDA). Seizures occur with tramadol even at recommended doses, and the risk may rise when the daily dose exceeds 400 mg (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination can be used with caution. The vortioxetine prescribing information names tramadol both among serotonergic drugs and among drugs that lower the seizure threshold, and advises caution with this combination (vortioxetine summary of product characteristics, SmPC, European Medicines Agency, EMA). If combined use is clinically justified, observe the patient closely, especially at the start of treatment and after dose increases (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Warn the patient in advance about the higher risk of serotonin syndrome (vortioxetine label, US Food and Drug Administration, FDA). If signs of serotonin syndrome appear, stop vortioxetine at once and start symptomatic treatment (vortioxetine SmPC, EMA). Under the US labels, also stop other serotonergic drugs, including tramadol, at once (vortioxetine and tramadol labels, FDA). Depending on the severity of symptoms, the Spanish tramadol SmPC advises considering a lower dose or stopping treatment. After serotonergic drugs are stopped, the condition usually improves quickly (tramadol SmPC, AEMPS). Tramadol is contraindicated in epilepsy not controlled by treatment. In people with epilepsy or a tendency to seizures, prescribe tramadol only if the circumstances require it. Exceed the daily dose of 400 mg only in special clinical circumstances (tramadol SmPC, AEMPS). In people with a history of seizures or unstable epilepsy, start vortioxetine with caution and stop it if seizures appear or become more frequent (vortioxetine SmPC, EMA). For people with depression or suicidal thoughts, the US tramadol label advises considering non-opioid analgesics. In people taking antidepressants, prescribe tramadol with caution (tramadol label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Tramadol hydrochloride tablets prescribing information (Amneal) (2026)– FDA label, Amneal Pharmaceuticals NY LLC, DailyMed setid 8ec4e4e5-a56e-4198-8428-6b770b9bf27d, revised 06/2026, sections 4, 5.9, 5.10, 7 and 17
- AEMPS: Ficha técnica: Tramadol, Adolonta 50 mg cápsulas (nº registro 59088), sección 4.5 (2025)– AEMPS, CIMA, nº registro 59088, revisión 11/2025, secciones 4.2, 4.4 y 4.5
- AEMPS: Ficha técnica: Tramadol (nº registro 59088), sección 4.4 (2025)– AEMPS, CIMA, nº registro 59088 (Adolonta 50 mg cápsulas duras), revisión 11/2025, secciones 4.3 y 4.4
- EMA: Ficha técnica: Vortioxetina – Brintellix (EU/1/13/891), sección 4.4 (2026)– EMA, SmPC Brintellix (EU/1/13/891), texto en CIMA nº 113891010, información del producto actualizada 19/01/2026, secciones 4.3, 4.4, 4.5 y 5.1
- FDA: TRINTELLIX (vortioxetine) tablets prescribing information (Takeda) (2025)– FDA, DailyMed setid 1a5b68e2-14d0-419d-9ec6-1ca97145e838 (Takeda Pharmaceuticals America), revisión 02/2025 (versión 18, vigente desde 05.03.2025), secciones 2.4, 4, 5.2 y 7.1